The Agaricus blazei-Based Mushroom Extract, Andosan™, Protects against Intestinal Tumorigenesis in the A/J Min/+ Mouse.

Authors:
Geir Hetland
Geir Hetland
Oslo University Hospital
Dag M Eide
Dag M Eide
University of Oslo
Norway
Jon M Tangen
Jon M Tangen
Ullevaal University Hospital
Norway
Mads H Haugen
Mads H Haugen
Institute for Cancer Research
Norway

PLoS One 2016 21;11(12):e0167754. Epub 2016 Dec 21.

Norwegian University of Life Sciences, Department of Food Safety and Infection Biology, Oslo, Norway.

Background: The novel A/J Min/+ mouse, which is a model for human Familial Adenomatous Polyposis (FAP), develops spontaneously multiple adenocarcinomas in the colon as well as in the small intestine. Agaricus blazei Murill (AbM) is an edible Basidiomycetes mushroom that has been used in traditional medicine against cancer and other diseases. The mushroom contains immunomodulating β-glucans and is shown to have antitumor effects in murine cancer models. Andosan™ is a water extract based on AbM (82%), but it also contains the medicinal Basidiomycetes mushrooms Hericeum erinaceus and Grifola frondosa.

Methods And Findings: Tap water with 10% Andosan™ was provided as the only drinking water for 15 or 22 weeks to A/J Min/+ mice and A/J wild-type mice (one single-nucleotide polymorphism (SNP) difference), which then were exsanguinated and their intestines preserved in formaldehyde and the serum frozen. The intestines were examined blindly by microscopy and also stained for the tumor-associated protease, legumain. Serum cytokines (pro- and anti-inflammatory, Th1-, Th2 -and Th17 type) were measured by Luminex multiplex analysis. Andosan™ treated A/J Min/+ mice had a significantly lower number of adenocarcinomas in the intestines, as well as a 60% significantly reduced intestinal tumor load (number of tumors x size) compared to control. There was also reduced legumain expression in intestines from Andosan™ treated animals. Moreover, Andosan™ had a significant cytotoxic effect correlating with apoptosis on the human cancer colon cell line, Caco-2, in vitro. When examining serum from both A/J Min/+ and wild type mice, there was a significant increase in anti-tumor Th1 type and pro-inflammatory cytokines in the Andosan™ treated mice.

Conclusions: The results from this mouse model for colorectal cancer shows significant protection of orally administered Andosan™ against development of intestinal cancer. This is supported by the finding of less legumain in intestines of Andosan™ treated mice and increased systemic Th1 cytokine response. The mechanism is probably both immuno-modulatory and growth inhibition of tumor cells by induction of apoptosis.

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0167754PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5176274PMC
July 2017
24 Reads

Publication Analysis

Top Keywords

a/j min/+
20
andosan™ treated
16
andosan™
9
min/+ mouse
8
mouse model
8
min/+ mice
8
intestines andosan™
8
a/j
6
min/+
5
cancer
5
intestines
5
mice
5
compared control
4
snp difference
4
andosan™ development
4
miceconclusions mouse
4
polymorphism snp
4
model colorectal
4
mice single-nucleotide
4
colorectal cancer
4

Altmetric Statistics

References

(Supplied by CrossRef)

Similar Publications